Edwards Lifesciences Corporation

Equities

EW

US28176E1082

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 02:12:02 2024-03-28 pm EDT 5-day change 1st Jan Change
95.3 USD +0.16% Intraday chart for Edwards Lifesciences Corporation +0.61% +24.93%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Stocks Edge -2- DJ
Edwards Lifesciences Longtime Chair To Retire DJ
Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
Edwards Lifesciences Likely to Benefit From 'Renaissance' in TMTT Segment, Says Morgan Stanley MT
Morgan Stanley Lifts Price Target on Edwards Lifesciences to $103 From $95, Sees 'Upside Risk' Amid Transcatheter Mitral & Tricuspid Therapies, Overweight Rating Kept MT
Oppenheimer Raises Edwards Lifesciences Price Target to $100 From $93, Maintains Outperform Rating MT
Edwards Lifesciences Insider Sold Shares Worth $1,319,696, According to a Recent SEC Filing MT
Edwards Lifesciences Insider Sold Shares Worth $1,320,149, According to a Recent SEC Filing MT
Edwards Lifesciences Announces Large, Real-World Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR CI
North American Morning Briefing : Stock Futures -2- DJ
BofA Securities Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $97 MT
Transcript : Edwards Lifesciences Corporation Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM
Edwards Lifesciences Insider Sold Shares Worth $2,543,737, According to a Recent SEC Filing MT
Edwards Lifesciences Insider Sold Shares Worth $620,923, According to a Recent SEC Filing MT
Edwards Lifesciences Insider Sold Shares Worth $267,911, According to a Recent SEC Filing MT
Edwards Lifesciences Insider Sold Shares Worth $711,272, According to a Recent SEC Filing MT
Edwards Lifesciences Insider Sold Shares Worth $4,040,854, According to a Recent SEC Filing MT
Edwards Lifesciences Insider Sold Shares Worth $944,155, According to a Recent SEC Filing MT
US FDA staff raises no new concerns about Abbott's heart device RE
Edwards Lifesciences Insider Sold Shares Worth $609,991, According to a Recent SEC Filing MT
UBS Adjusts Edwards Lifesciences Price Target to $92 From $84, Maintains Neutral Rating MT
Canaccord Genuity Adjusts Price Target on Edwards Lifesciences to $86 From $81, Maintains Hold Rating MT
Fed officials fail to convince investors, who are focused on earnings Our Logo
Oppenheimer Adjusts Edwards Lifesciences Price Target to $93 From $90, Maintains Outperform Rating MT
Chart Edwards Lifesciences Corporation
More charts
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - heart valves and surgery products (67.9%); - hemodynamic monitoring systems (15.5%); - other (16.6%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
95.15 USD
Average target price
92.11 USD
Spread / Average Target
-3.19%
Consensus
  1. Stock
  2. Equities
  3. Stock Edwards Lifesciences Corporation - Nyse
  4. News Edwards Lifesciences Corporation
  5. Canaccord Genuity Adjusts Edwards Lifesciences Price Target to $76 From $68, Maintains Hold Rating